Báo cáo y học: "Clinical and Molecular Allergy: a new open access journal that addresses rapidly evolving information in the field of allergy and immunology" pptx

BioMed Central
Page 1 of 2
(page number not for citation purposes)
Clinical and Molecular Allergy
Open Access
Editorial
Clinical and Molecular Allergy: a new open access journal that
addresses rapidly evolving information in the field of allergy and
immunology
Guha Krishnaswamy*
1
and David S Chi
2
Address:
1
Professor of Medicine, Chief of Allergy and Immunology, James H. Quillen College of Medicine, East Tennessee State University, USA
and
2
Professor of Medicine and Chief, Biomedical Research, James H. Quillen College of Medicine, East Tennessee State University, USA
Email: Guha Krishnaswamy* - ; David S Chi -
* Corresponding author
Clinical and Molecular Allergy is an Open Access, peer-
reviewed online journal that addresses all clinical and
molecular aspects of allergic disease.
The genomics revolution of the 21
st
century has led to
enormous advances in our understanding of allergic and
immunological disease. The use of transgenic and knock
out methodologies, stem cell biology, gene cloning and
sequencing, and high throughput technology has revolu-

tionized medicine. Discovery of families of cytokines and
chemokines, novel signaling mechanisms, and of new
mediators and inflammatory pathways have led to pivotal
insights into the basis of allergic and immunological dis-
eases. This has led to the generation of new treatment
strategies such as monoclonal antibodies, cytokine inhib-
itors, new immunomodulators and gene therapy.
At present, there is no journal dedicated specifically to
both the clinical and molecular aspects of allergic dis-
eases. In starting Clinical and Molecular Allergy, we hope to
present timely reviews and mechanism-oriented reports
that will open up new avenues for research and bring
together research communities from across the globe. A
strong emphasis will be placed on education and timely
reviews of molecular diagnostic technology and molecu-
lar biotherapeutics, which will constitute an ever-increas-
ing aspect of our existence in the future. Reviews of these
areas will allow clinicians to learn and share their experi-
ences and understanding of these advances.
Clinical and Molecular Allergy is Open Access meaning it is
freely and universally accessible online, it is archived in at
least one internationally recognized free access repository,
and its authors retain copyright, allowing anyone to
reproduce or disseminate articles, according to the Bio-
Med Central copyright and licence agreement [1]. Clinical
and Molecular Allergy's articles are archived in PubMed
Central [2], the US National Library of Medicine's full-text
repository of life science literature, and also in repositories
at the University of Potsdam in Germany [3], at INIST in
France [4] and in e-Depot [5], the National Library of the

Netherlands' digital archive of all electronic publications.
This will allow scientists and physicians from around the
world to share in the exciting advances. Information will
be disseminated around the world instantly with no cost
for access. With the high cost of hard copy journals, a lot
of libraries, clinics, and medical schools in many coun-
tries are struggling with limited resources to gain access to
the new information. Our Open Access journal may in
some small way narrow this information gap. It will also
decrease the use and waste of paper and help preserve our
environment.
The Journal has several aspects that will appeal to both
researchers and clinicians. The Journal's contents include
original articles of clinical studies and bench research,
case reports, mini reviews, commentaries and guest edito-
rials. Manuscripts that deal with the clinical and molecu-
lar basis of allergic disease will remain the major focus for
this Journal. Case reports of clinical significance that pro-
vide some molecular insight into common or rare diseases
Published: 04 February 2004
Clinical and Molecular Allergy 2004, 2:1
Received: 23 January 2004
Accepted: 04 February 2004
This article is available from: />© 2004 Krishnaswamy and Chi; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permit-
ted in all media for any purpose, provided this notice is preserved along with the article's original URL.
Publish with BioMed Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright
Submit your manuscript here:
/>BioMedcentral
Clinical and Molecular Allergy 2004, 2 />Page 2 of 2
(page number not for citation purposes)
will also be highly sought. We will publish novel and
innovative articles related to both the clinical treatment of
allergic and immunological disease and the molecular
biology of inflammatory cells, cytokines, and other fac-
tors. Mini reviews, commentaries and editorials will be
systematically and periodically solicited.
In the age of information technology, online journals pro-
vide novel ways of disseminating medical information.
We are grateful to our publisher BioMed Central for pro-
viding us with the opportunity to create, develop and
build Clinical and Molecular Allergy. The submission, peer
review, and publication of manuscripts will be done by an
efficient, online process. This method will shorten the
time for publication of the peer reviewed information.
Articles will be published online immediately upon
acceptance and soon after listed in PubMed.
Clinical and Molecular Allergy is a new and Open Access
publication. We hope that you will support us by submit-
ting your manuscripts to the Journal. Information is avail-
able at the following URL: http://
www.clinicalmolecularallergy.com/manuscript/. With

your assistance, it will grow to become a distinguished
journal in its field.
Guha Krishnaswamy, M.D., FACP., FCCP
David S. Chi, Ph.D., FAAM., FAMLI
Editors-In-Chief
References
1. BioMed Central Open Access Charter [medcen
tral.com/info/about/charter]
2. PubMed Central [
]
3. Potsdam [ />]
4. INIST [ />]
5. e-Depot [ />]